O
OrbiMed Portfolio holdings
AUM
$4.59B
1-Year Est. Return
131.45%
This Fund
S&P 500
1 Year Est. Return
+131.45%
AUM
$4.59B
AUM Growth
-$301M
(-6.2%)
Holding
130
Top Buys
| 1 | +$109M | |
| 2 | +$76.6M | |
| 3 | +$43.7M | |
| 4 |
Mineralys Therapeutics
MLYS
|
+$31.5M |
| 5 |
uniQure
QURE
|
+$28.3M |
Top Sells
| 1 | +$87M | |
| 2 | +$65.3M | |
| 3 | +$61M | |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$57.8M |
| 5 |
Cigna
CI
|
+$56.4M |
Sector Composition
| 1 | Healthcare | 99.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Pfizer
PFE
$149B
| $54.7M | 1.19% |
1,946,500
+293,600
|
|
||
27
Dyne Therapeutics
DYN
$3.2B
| $52.9M | 1.15% |
2,917,884
+715,700
|
|
||
28
Natera
NTRA
$32B
| $52.4M | 1.14% |
262,000
-103,800
|
|
||
|
ABVX
29
Abivax
ABVX
$10.6B
| $51.9M | 1.13% |
465,700
+97,800
|
|
||
|
UPB
30
Upstream Bio Inc
UPB
$455M
| $51.2M | 1.12% |
5,693,589
|
|
||
31
Danaher
DHR
$129B
| $50.4M | 1.1% |
265,800
-34,000
|
|
||
|
CAI
32
Caris Life Sciences
CAI
$4.73B
| $50.2M | 1.09% |
2,806,811
-309,200
|
|
||
33
Avita Medical
RCEL
$133M
| $42.5M | 0.93% |
+544,895
|
|
||
34
Ascendis Pharma A/S
ASND
$13.8B
| $41.6M | 0.91% |
181,977
+10,000
|
|
||
35
Shattuck Labs
STTK
$456M
| $40.5M | 0.88% |
6,306,127
|
|
||
36
Guardant Health
GH
$17.2B
| $40.2M | 0.88% |
+435,200
|
|
||
|
37
Alnylam Pharmaceuticals
ALNY
$40.3B
| $39.4M | 0.86% |
119,000
-169,800
|
|
||
38
Prelude Therapeutics
PRLD
$312M
| $37.3M | 0.81% |
10,909,256
|
|
||
39
Crinetics Pharmaceuticals
CRNX
$3.75B
| $36.3M | 0.79% |
999,000
|
|
||
40
Axsome Therapeutics
AXSM
$12.1B
| $36.2M | 0.79% |
213,921
-39,200
|
|
||
|
41
uniQure
QURE
$1.8B
| $34.9M | 0.76% |
2,136,149
+1,398,749
|
|
||
42
Oric Pharmaceuticals
ORIC
$875M
| $34.1M | 0.74% |
2,693,929
-947,827
|
|
||
43
Elevance Health
ELV
$85.4B
| $33.6M | 0.73% |
114,700
+15,600
|
|
||
44
Relmada Therapeutics
RLMD
$756M
| $32.8M | 0.72% |
4,715,864
+2,105,264
|
|
||
45
Forte Biosciences
FBRX
$391M
| $31M | 0.68% |
1,196,955
|
|
||
46
Trevi Therapeutics
TRVI
$2.01B
| $29.3M | 0.64% |
2,454,400
-736,300
|
|
||
47
Esperion Therapeutics
ESPR
$806M
| $29M | 0.63% |
10,570,300
+4,604,802
|
|
||
48
Neuropace
NPCE
$564M
| $27.6M | 0.6% |
2,096,527
-309,808
|
|
||
49
Rhythm Pharmaceuticals
RYTM
$6.05B
| $27.3M | 0.6% |
314,100
+74,300
|
|
||
50
Thermo Fisher Scientific
TMO
$183B
| $22.9M | 0.5% |
46,500
|
|